Mitsui Chemicals branches out to beef up business

Kovac, Matt
October 2006
ICIS Chemical Business;10/9/2006, Vol. 1 Issue 38, p12
Trade Publication
This article reports on the decision of Mitsui Chemicals of Japan to acquire Daiichi Sankyo's agrichemical business. The deal is part of Mitsui's plan to broaden its product offering and improve research and development. The deal will increase the annual sales of Mitsui's agrichemical division and will also expand Mitsui's sales network and strengthen its development pipeline.


Related Articles

  • Mitsui to Acquire Agchems Firm. Young, Ian // Chemical Week;10/11/2006, Vol. 168 Issue 34, p17 

    The article reports on the move of Mitsui Chemicals to acquire agricultural chemicals company Sankyo Agro from Sankyo Co., part of the Daiichi Sankyo group. The acquisition will be effective on March 30, 2007, Mitsui says. Sankyo Agro will in the meantime take over wood preservative and...

  • Japan's Daiichi exits Sun Pharma.  // FRPT- Chemical Snapshot;5/3/2015, p16 

    The article discusses the sale of all holdings of Japanese drug maker Daiichi Sankyo in Sun Pharmaceutical Industries in India following the completion of the merger of Ranbaxy based on Gurgaon and Sun Pharma in 2015.

  • Daiichi Sankyo to Purchase German Biotech for $235M. Hollingsworth, Catherine // BioWorld Today;5/22/2008, Vol. 19 Issue 100, p1 

    This article talks about the announcement by Daiichi Sankyo Co. Ltd. that it is buying privately held German biotechnology firm U3 Pharma AG for $235 million. Daiichi Sankyo will purchase 100 percent of U3's stock and make a one-time payment of €150 million. The purchase will complement...

  • Daiichi Sankyo Bolsters Pipe with $935M Plexxikon Buy. Wall, Tom // BioWorld Today;3/2/2011, Vol. 22 Issue 41, p1 

    The article reports on the acquisition of Plexxikon Inc. of California and its melanoma drug PLX4032 by Japanese company Daiichi Sankyo Co. Ltd. It cites other major U.S. oncology buys made by Japanese makers including Eisai Company's purchase of Ligand Pharmaceuticals Inc. Plexxicon chief...

  • The takeover code.  // Money Today;Nov2010, p3 

    This article assesses an increase in the open offer size from 20 percent to 100 percent recommended by the takeover committee of the Securities and Exchange Board of India (SEBI) in 2010. It highlights the intention of the strategy such as to help small investors gain from takeovers. It cites...

  • 'Ranbaxy-Sun Pharma merger deal likely to close by 2014 end'.  // FRPT- Chemical Snapshot;4/27/2014, p11 

    The article discusses a statement released by drug maker Daiichi Sankyo that the 4 billion dollar merger between pharmaceutical companies Sun Pharma and Ranbaxy is projected to be settled by end of 2014. It also offers a targeted time-frame for the merger deal transaction to be settled. Benefits...

  • Daiichi Sankyo: an alternative acquisition strategy.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 7, p23 

    The article reports on the plan of Daiichi Sankyo Co. to gain a majority control over Ranbaxy Pharmaceuticals Inc. Japanese pharmaceutical Daiichi has announced that it intends to take a majority control over India's biggest drug maker, Ranbaxy, in a deal which could be worth up to $4.6 billion....

  • Daiichi Sankyo to Buy German Biotech for $235M.  // Bioworld Week;5/26/2008, Vol. 16 Issue 21, p1 

    The article reports on the acquisition of U3 Pharma AG, a biotechnology company, by Daiichi Sankyo Co. Ltd. in Martinsried, Germany. The Tokyo, Japan-based Daiichi Sankyo will purchase 100% of the stock and will make a one-time payment of US$235 million for U3. It is stated that the closing of...

  • Daiichi Sankyo Snage Ranbaxy for $4.6 Billion. Houlton, Sarah // Pharmaceutical Executive;Aug2008, Vol. 29 Issue 8, p16 

    The article reports on the selling of Indian pharmaceutical company, Ranbaxy Pharmaceuticals Inc.'s controlling stake in its business to Daiichi Sankyo Co. Ltd. of Japan. The $4.6 billion acquisition will leave the Indian company with its own name and chief executive Malvinder Singh. Dilip Shah,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics